News
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Hims & Hers is pitching consumers on a GLP-1 weight loss injection that will cost 85% less than brand-name drugs like Wegovy.
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization.
The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy – Hagens Berman ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results